Coronary artery disease (Atheroscelerosis). Atherosclerotic heart disease
Conditions
Interventions
Intervention 1: The intervention group receives 5mg folic acid (powdered) in capsules . 5mg folic acid (1 capsule) daily for 2 months. Intervention 2: The control group receives placebo also powdered
Treatment - Drugs
Placebo
The intervention group receives 5mg folic acid (powdered) in capsules . 5mg folic acid (1 capsule) daily for 2 months.
The control group receives placebo also powdered in capsules. 1 capsule daily for 2 months.
Sponsors
Vice chancellor for Research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Major Inclusion criteria: Type II diabetic patients; Major exclusion criteria: History of anti angina treatment or revascularization; Evidence of Q wave in ECG referring to previous MI; ECG based ST changes due to ischemia; Active asthma; Type II cardiac block or more;
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myocardial perfusion. Timepoint: Before and two months after intervention. Method of measurement: MPI. | — |
Secondary
| Measure | Time frame |
|---|---|
| TID. Timepoint: After MPI. Method of measurement: QPS software.;Hemocysteine blood level. Timepoint: Before MPI. Method of measurement: Blood level of hemocysteine. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Mohammad Eftekhari
Research institute for nuclear medicine, Tehran university of medical sciences
Outcome results
None listed